Vol 70, No 4 (2019)

Date published: 2019-08-14

Table of Contents

open access

Letter to Readers

Letter to Readers [List do Czytelników]

Beata Kos-Kudła

Endokrynologia Polska 2019;70(4):1-2.
Original papers

Efficacy and safety of high-dose long-acting repeatable octreotide as monotherapy or in combination with pegvisomant or cabergoline in patients with acromegaly not adequately controlled by conventional regimens: results of an open-label, multicentre study

Annamaria Colao, Wojciech Zgliczyński, Jan Komorowski, Beata Kos-Kudła, Antoine Tabarin, Veronique Kerlan, Francesco M. Minuto, Carla Scaroni, Marek Bolanowski

DOI: 10.5603/EP.a2019.0023
Pubmed: 31274183
Endokrynologia Polska 2019;70(4):305-312.

Capecitabine and temozolomide combination for treatment of high-grade, well-differentiated neuroendocrine tumour and poorly-differentiated neuroendocrine carcinoma — retrospective analysis

Wojciech Rogowski, Ewa Wachuła, Anita Gorzelak, Aneta Lebiedzińska, Violeta Sulżyc-Bielicka, Ewa Iżycka-Świeszewska, Jakub Żołnierek, Beata Kos-Kudła

DOI: 10.5603/EP.a2019.0010
Pubmed: 30843182
Endokrynologia Polska 2019;70(4):313-317.

The level of IL-35 in the circulation of patients with Graves’ disease

Meng Shuai, Yan Ni, Xu Jian, Shuangtao He, Jin-an Zhang

DOI: 10.5603/EP.a2019.0018
Pubmed: 30938833
Endokrynologia Polska 2019;70(4):318-322.

Is treatment of type 1 diabetes mellitus (insulin therapy, metabolic control) optimal for preventing cardiovascular autonomic neuropathy?

Łukasz Pawliński, Joanna Gastoł, Mateusz Fiema, Bartłomiej Matejko, Beata Kieć-Wilk

DOI: 10.5603/EP.a2019.0011
Pubmed: 30845344
Endokrynologia Polska 2019;70(4):323-329.

The value of the free androgen index depends on the phenotype of polycystic ovary syndrome — a single-centre experience

Katarzyna Ożga, Magdalena Krzyczkowska- Sendrakowska, Alicja Hubalewska- Dydejczyk, Aleksandra Gilis-Januszewska, Maciej Ratajczak, Magdalena Ratajczak, Zlata Chaykivska, Robert Jach

DOI: 10.5603/EP.a2019.0017
Pubmed: 30938834
Endokrynologia Polska 2019;70(4):330-335.

Cardiometabolic risk factors in young women with macroprolactinaemia

Robert Krysiak, Bogdan Marek, Bogusław Okopień

DOI: 10.5603/EP.a2019.0013
Pubmed: 30845340
Endokrynologia Polska 2019;70(4):336-341.

New insights into clinical features, karyotypes, and age at diagnosis in women with Turner syndrome

Jakub Frelich, Tomasz Irzyniec, Katarzyna Lepska, Wacław Jeż

DOI: 10.5603/EP.a2019.0016
Pubmed: 31073987
Endokrynologia Polska 2019;70(4):342-349.
Review article

Trabecular bone score (TBS) as a noninvasive and complementary tool for clinical diagnosis of bone structure in endocrine disorders

Jowita Halupczok-Żyła, Łukasz Gojny, Marek Bolanowski

DOI: 10.5603/EP.a2019.0022
Endokrynologia Polska 2019;70(4):350-356.
REVIEWS — Postgraduate Education

Surgical approach to differentiated thyroid cancers (DTC) in children [Specyfika leczenia chirurgicznego zróżnicowanych raków tarczycy (ZRT) u dzieci]

Agnieszka Czarniecka, Grzegorz Woźniak, Aleksandra Kropińska, Barbara Jarząb, Daria Handkiewicz-Junak

DOI: 10.5603/EP.a2019.0033
Endokrynologia Polska 2019;70(4):357-366.

Current surgical management in RET mutation carriers [Aktualne postępowanie chirurgiczne u nosicieli mutacji proto-onkogenu RET]

Agnieszka Czarniecka, Małgorzata Oczko-Wojciechowska, Anna Hajduk, Marcin Zeman, Barbara Jarzab

DOI: 10.5603/EP.a2019.0021
Endokrynologia Polska 2019;70(4):367-379.
Case report

Capecitabine plus temozolomide in well- or moderately-differentiated primary atypical neuroendocrine tumours — single-centre experience of two cases

Anna La Salvia, Maria Pia Brizzi, Leonardo Muratori, Elena Trevisi, Massimo Di Maio, Giorgio Vittorio Scagliotti

DOI: 10.5603/EP.a2018.0076
Pubmed: 30359462
Endokrynologia Polska 2019;70(4):380-383.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl